Document Detail


Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty.
MedLine Citation:
PMID:  15973655     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Adjunctive use of abciximab during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) improves clinical outcome. This study addresses the outcome of patients with AMI treated with abciximab, initiated either before transport to a PCI center (early group) or immediately upon arrival at the catheterization laboratory (late group) for primary PCI. Of 446 consecutive patients with AMI, angiographic data and clinical complications were evaluated up to 6 months after primary PCI. Patients received abciximab before transport (early group; n = 138) or just before the intervention (late group; n = 308). Baseline data, including transport time (45 +/- 15 min; range, 15-60 min), were comparable in both groups. Early reperfusion was more prevalent in the early group (35% vs. late 19%; P < 0.001). Furthermore, a better final TIMI 3 flow was noted in the early group (91% vs. late 83%; P = 0.05). Although mortality reduction attributable to early abciximab treatment could not be demonstrated, major adverse cardiac events (MACE) occurred in 27% in the early group and 36% in the late group (P = 0.05). Revascularization rates were similar, but repeat acute coronary syndromes were less frequent in the early group (11% vs. late group 20%; P = 0.04). In multivariate analysis, cardiogenic shock, out-of-hospital cardiac arrest, and previously known coronary artery disease were independent predictors of higher MACE rate, whereas early reperfusion and final TIMI 3 flow reduced 6-month MACE rate. Abciximab pretreatment of patients with AMI for primary PCI results in better initial and final TIMI flow and tends to improve 6-month clinical outcome.
Authors:
Saskia L M A Beeres; Pranobe V Oemrawsingh; Hazem M Warda; Ratna Bechan; Douwe E Atsma; J Wouter Jukema; Ernst E van der Wall; Martin J Schalij
Related Documents :
23761565 - Unusually located left ventricular outflow myxoma: a brief review of the literature.
21114705 - Tachycardia transition during ablation of persistent atrial fibrillation.
23523545 - Biodegradation and heart retention of polymeric microparticles in a rat model of myocar...
24091585 - Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of...
12460385 - Reconstruction of right ventricular outflow tract with stentless xenografts in ross pro...
16215385 - Cardioprotective effects of acute isovolemic hemodilution in a rat model of transient c...
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  65     ISSN:  1522-1946     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-07-27     Completed Date:  2005-12-21     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  478-83     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal / administration & dosage*
Coronary Angiography*
Coronary Artery Disease / epidemiology,  radiography*,  therapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
Immunoglobulin Fab Fragments / administration & dosage*
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction / epidemiology,  radiography*,  therapy*
Netherlands
Platelet Aggregation Inhibitors / administration & dosage*
Postoperative Complications / epidemiology,  etiology,  mortality
Predictive Value of Tests
Risk Factors
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hyperexcitable polymodal and insensitive nociceptors in painful human neuropathy.
Next Document:  Selective versus exclusive use of sirolimus-eluting stent implantation in multivessel coronary arter...